Prana selects lead PD drug candidate for development
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Quintiles Makes Second Investment in Prana
- Prana`s PBT2 Phase II trial receives funding from ADDF
- Prana Raises A$6.19 million in a Private Placement
- Prana accelerates PBT2 commercial development
- PBT2 - Directly Restores Neurons Critical to Cognition
Later from Alterity Therapeutics
- FDA Orphan Drug Designation for PBT2 for Huntington Disease
- Prana announces $6.5 million R&D refund
- New Reach2HD data presented at American Neurological Assoc.
- Prana announces $4.8 million R&D refund
- Prana provides regulatory update for PBT2
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics